European Journal of Medicinal Chemistry p. 359 - 371 (2018)
Update date:2022-08-05
Pati, Maria Laura
Niso, Mauro
Spitzer, Dirk
Berardi, Francesco
Contino, Marialessandra
Riganti, Chiara
Hawkins, William G.
Abate, Carmen
The aggressiveness of pancreatic cancer urgently requires more efficient treatment options. Because the sigma-2 (σ2) receptor was recently proposed as a promising target for pancreatic cancer therapy, we explored our previously developed multifunctional thiosemicarbazones, designed to synergistically impair cell energy levels, by targeting σ2 and P-gp proteins and chelating Iron. A deconstruction approach was herein applied by removing one function at a time from the potent multifunctional thiosemicarbazones 1 and 2, to investigate the contribution to cytotoxicity of each target involved. The results from in vitro (panel of pancreatic tumor cells) and in vivo experiments (C57BL/6 bearing KP02 tumor), suggest that while the multifunctional activity was not required for the antitumor activity of these thiosemicarbazones, σ2-targeting appeared to allow alternative tumor cell death mechanisms, leading to potent and less toxic off-targets toxicities compared to other thiosemicarbazones devoid of σ2-targeting.
View MoreAirsea(Taizhou) Pharmaceutical Limited(expird)
Contact:+86-576-88057622
Address:Dubei, Duqiao, Linhai, Taizhou, Zhejiang, China Zip: 317016
Xi'an Costrong Pharmaceutical Co., Ltd.
Contact:029- 68576496
Address:Room 2004,Shuibao Building,No.190,South Erhuan Rd, Yanta District,Xi'an,Shaan Xi,China
Beijing Cooperate Pharmaceutical Co.,Ltd
Contact:86-01060279497
Address:No.507,Building 4,Tianhua Street, Biomedicine industrial Base
Suzhou Lixin Pharmaceutical Co., Ltd.
Contact:86-512-88169812
Address:21 Tangxi Road, Suzhou New District, Suzhou 215151
Suzhou BEC Fine Chemicals Co., Ltd.
website:http://www.bek.com.cn
Contact:0512-68095917 18913193865
Address:6, Jin Shan Road, Suzhou New District, 215011 China Suzhou Nations Pharmaceutical Innovation Center Inside
Doi:10.1002/hlca.19800630408
(1980)Doi:10.1002/hlca.19490320122
(1949)Doi:10.1021/jo00333a003
(1981)Doi:10.1139/v87-448
(1987)Doi:10.1016/S0960-894X(01)00499-1
(2001)Doi:10.1007/BF00503479
(1981)